Bristol Myers Squibb (BMY) Stock Forecast & Price Target

$63.10 +1.98 (+3.23%)

Closing price 03:59 PM Eastern

Extended Trading

$63.34 +0.24 (+0.39%)

As of 07:59 PM Eastern

Compare

Bristol Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 30 Analyst Ratings

Sell
1

Hold
15

Buy
14

Based on 30 Wall Street analysts who have issued ratings for Bristol Myers Squibb in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 30 analysts, 1 has given a sell rating, 15 have given a hold rating, 11 have given a buy rating, and 3 have given a strong buy rating for BMY.

Consensus Price Target

$64.88
2.83% Upside

According to the 30 analysts' twelve-month price targets for Bristol Myers Squibb, the average price target is $64.88. The highest price target for BMY is $76.00, while the lowest price target for BMY is $41.00. The average price target represents a forecasted upside of 2.83% from the current price of $63.10.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bristol Myers Squibb and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BMY Analyst Ratings Over Time

Type	Current Forecast 10/22/25 to 10/22/26	1 Month Ago 9/22/25 to 9/22/26	3 Months Ago 7/24/25 to 7/24/26	1 Year Ago 10/22/24 to 10/22/25
Strong Buy	3 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	1 Strong Buy rating(s)
Buy	11 Buy rating(s)	12 Buy rating(s)	9 Buy rating(s)	4 Buy rating(s)
Hold	15 Hold rating(s)	14 Hold rating(s)	13 Hold rating(s)	13 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$64.88	$65.40	$61.29	$57.23
Forecasted Upside	2.83% Upside	5.13% Upside	-1.23% Downside	29.01% Upside
Consensus Rating	Moderate Buy	Hold	Hold	Hold

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Bristol Myers Squibb Stock vs. The Competition

Type	Bristol Myers Squibb	Healthcare Companies	Broader Market
Consensus Rating Score	2.53	2.32	2.53
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	2.83% Upside	1,333.58% Upside	15.80% Upside
News Sentiment Rating	Positive News See Recent BMY News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/19/2026	Royal Bank Of Canada 2 of 5 stars	Trung Huynh Not Rated	Reiterated Rating	Sector Perform
10/16/2026	The Goldman Sachs Group 3 of 5 stars	Asad Haider 5 of 5 stars	Upgrade	Hold ➝ Strong-Buy
10/13/2026	Sanford C. Bernstein 3 of 5 stars		Reiterated Rating	Market Perform
10/13/2026	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Mohit Bansal Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Equal Weight	$65.00 ➝ $60.00	+6.22%
10/12/2026	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Akash Tewari Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$76.00	+31.86%
10/12/2026	William Blair Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Market Perform
10/9/2026	Bank of America Subscribe to MarketBeat All Access to unlock brokerage rankings	Tim Anderson Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target		$71.00 ➝ $66.00	+11.52%
10/8/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Neutral	$51.00 ➝ $53.00	-10.45%
10/8/2026	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Carter Gould Subscribe to MarketBeat All Access to unlock analyst rankings	Lower Target	Neutral	$59.00 ➝ $53.00	-11.20%
10/7/2026	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Terence Flynn Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Underweight	$40.00 ➝ $41.00	-31.20%
Get the Latest News and Ratings for BMY and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.
10/5/2026	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	David Risinger Subscribe to MarketBeat All Access to unlock analyst rankings	Downgrade	Outperform ➝ Market Perform	$73.00 ➝ $59.00	-3.53%
9/23/2026	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Hold ➝ Strong-Buy
9/16/2026	Piper Sandler Subscribe to MarketBeat All Access to unlock brokerage rankings	David Amsellem Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Overweight	$75.00 ➝ $82.00	+28.75%
9/10/2026	HSBC Subscribe to MarketBeat All Access to unlock brokerage rankings	Rajesh Kumar Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Hold	$60.00 ➝ $65.00	+0.84%
8/18/2026	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Hold (C+) ➝ Buy (B-)
8/5/2026	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings		Initiated Coverage	Market Perform ➝ Strong-Buy
8/5/2026	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings		Initiated Coverage	Hold ➝ Buy
8/5/2026	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Downgrade	Buy ➝ Neutral
8/5/2026	Roth Capital Subscribe to MarketBeat All Access to unlock brokerage rankings		Initiated Coverage	Buy	$75.00	+17.22%
8/5/2026	Argus Subscribe to MarketBeat All Access to unlock brokerage rankings	Jasper Hellweg Subscribe to MarketBeat All Access to unlock analyst rankings	Upgrade	Hold ➝ Buy	$75.00	+13.92%
8/4/2026	Daiwa Securities Group Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Neutral	$53.00 ➝ $66.00	+11.52%
8/3/2026	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Geoff Meacham Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Neutral	$66.00 ➝ $70.00	+6.98%
7/31/2026	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Seamus Fernandez Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$72.00 ➝ $75.00	+15.42%
7/31/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Chris Schott Subscribe to MarketBeat All Access to unlock analyst rankings	Boost Target	Overweight	$67.00 ➝ $73.00	+12.08%
7/31/2026	Truist Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Robyn Karnauskas Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Buy	$65.00 ➝ $70.00	+7.72%
7/27/2026	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings		Reiterated Rating	Market Perform
2/24/2026	Berenberg Bank Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Hold	$57.00 ➝ $60.00	+1.38%
2/19/2026	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Emily Field Subscribe to MarketBeat All Access to unlock analyst rankings	Initiated Coverage	Underweight ➝ Overweight	$75.00	+24.33%
1/9/2026	Scotiabank Subscribe to MarketBeat All Access to unlock brokerage rankings	Louise Chen Subscribe to MarketBeat All Access to unlock analyst rankings	Reiterated Rating	Sector Perform	$53.00 ➝ $60.00	+7.82%
12/17/2025	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access to unlock brokerage rankings		Boost Target	Hold	$52.00 ➝ $65.00	+9.83%
10/2/2025	Dbs Bank Subscribe to MarketBeat All Access to unlock brokerage rankings		Upgrade	Moderate Buy
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Alexandria Hammond Subscribe to MarketBeat All Access to unlock analyst rankings	Initiated Coverage	Peer Perform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 11:29 PM ET.

Should I Buy Bristol Myers Squibb Stock? BMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, October 20, 2026. Please send any questions or comments about these Bristol Myers Squibb pros and cons to contact@marketbeat.com.

Bristol Myers Squibb
Bull Case

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

Bristol-Myers Squibb shares are currently trading at $61.76, which is below the average analyst price target of $64.88, suggesting potential for upside as the stock has recently received a "Strong-Buy" upgrade from Goldman Sachs.
The company offers a high dividend yield of 4.22%, providing a steady income stream for investors, with a recent quarterly dividend of $0.63 per share declared for payment in November 2026.
Bristol-Myers Squibb demonstrated strong financial performance in the second quarter of 2026, beating consensus estimates with earnings per share of $2.04 compared to the expected $1.60, and revenue of $12.97 billion against an estimate of $11.74 billion.
The stock has a low beta of 0.19, indicating that it is less volatile than the overall market, which can be attractive to investors seeking stability in their portfolio.
Institutional investors are showing increased confidence, with firms like Assenagon Asset Management S.A. raising their positions by 32.5% in the third quarter and TD Waterhouse Canada Inc. boosting its stake by 145.7%.

Bristol Myers Squibb
Bear Case

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

The company has a high debt-to-equity ratio of 1.89, which indicates a significant level of leverage and could pose financial risks if interest rates rise or earnings decline.
Bristol-Myers Squibb missed its earnings expectations in the first quarter of 2026, reporting earnings per share of $1.26 compared to the consensus estimate of $1.65, which may signal underlying challenges in profitability.
The stock is currently trading below its 50-day simple moving average of $63.43, suggesting short-term downward momentum and potential weakness in the near term.
Insider selling activity has been observed, with SVP Phil M. Holzer selling 500 shares in August 2026 and EVP David V. Elkins selling 30,000 shares in April 2026, which could indicate a lack of confidence from company leadership.
The company's dividend payout ratio is 55.51%, which is relatively high and may limit the company's ability to reinvest in growth or manage debt, especially if earnings face pressure.

BMY Forecast - Frequently Asked Questions

According to the research reports of 30 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol Myers Squibb is $64.88, with a high forecast of $76.00 and a low forecast of $41.00.

30 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bristol Myers Squibb in the last twelve months. There is currently 1 sell rating, 15 hold ratings, 11 buy ratings and 3 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" BMY shares.

According to analysts, Bristol Myers Squibb's stock has a predicted upside of 2.83% based on their 12-month stock forecasts.

Over the previous 90 days, Bristol Myers Squibb's stock had 6 upgrades and 3 downgrades by analysts.

Bristol Myers Squibb has been rated by research analysts at Argus, Bank of America, BMO Capital Markets, Cantor Fitzgerald, Citigroup, Daiwa Securities Group, Guggenheim, HSBC, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Morgan Stanley, Piper Sandler, Raymond James Financial, Roth Capital, Rothschild & Co Redburn, Royal Bank Of Canada, Sanford C. Bernstein, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, Wells Fargo & Company, William Blair, and Zacks Research in the past 90 days.

Analysts like Bristol Myers Squibb more than other "healthcare" companies. The consensus rating for Bristol Myers Squibb is Moderate Buy while the average consensus rating for "healthcare" companies is Hold. Learn more on how BMY compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Bristol Myers Squibb Recommendations

MarketBeat monitors more than a dozen sources for Bristol Myers Squibb analyst ratings, with the most recent rating issued on 10/19/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BMY Analyst Ratings Over Time

BMY Analyst Recommendations By Month

BMY Price Targets by Month

Bristol Myers Squibb Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Bristol Myers Squibb Stock? BMY Pros and Cons Explained

Bristol Myers Squibb
Bull Case

Bristol Myers Squibb
Bear Case

BMY Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Bristol Myers Squibb Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bristol Myers Squibb (BMY) Stock Forecast & Price Target

Bristol Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

BMY Analyst Ratings Over Time

BMY Analyst Recommendations By Month

BMY Price Targets by Month

Bristol Myers Squibb Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Bristol Myers Squibb Stock? BMY Pros and Cons Explained

Bristol Myers Squibb Bull Case

Bristol Myers Squibb Bear Case

BMY Forecast - Frequently Asked Questions

What is Bristol Myers Squibb's forecast for 2026?

Should I buy or sell Bristol Myers Squibb stock right now?

Does Bristol Myers Squibb's stock price have much upside?

Has Bristol Myers Squibb been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Bristol Myers Squibb?

Do Wall Street analysts like Bristol Myers Squibb more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Bristol Myers Squibb Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Bristol Myers Squibb
Bull Case

Bristol Myers Squibb
Bear Case